CUV

1.85%

$13.28 clinuvel pharmaceuticals limited

Is there buy volume restriction(based on average volume sold )...

First 5 Last

Share
Profile

Follow
ben1976

134 Posts.

23

22/04/24

11:49

Post #: 73454531
Share

Originally posted by Silverchair: ↑

Good appointments. Dr Rodenburger helped achieve the FDA approval for Clinuvel in the past with EPP, also knows Vitiligo and obtaining FDA approval in this blockbuster should be easier as the drug is already approved with a long track record of safety and showing efficacy would appear to be quite simple relatively. Approval for a new indication easier than a whole new drug application, with safety well established, so hopefully this becomes the standard of care in just a handful of years.

US investor relations also good, first job needs to be the basic upgrade from the obscure pink sheets so attracting investors will be an easier task for him. Clinuvel said it only took one investor buying a lot of shares in Sep 2021 to take the price over $40 and the investment case is much stronger now with the Phase 3 trial running and stated revenue targets of $490 - $570 Million USD in years 1-2 on top of an already very profitable enterprise which doesn't have to share profits with 'big Pharma'. Great scenario just calculate likelihood of Vitiligo approval, pretty good chance IMO and only one analyst has done this and come up with a PT ~$50. Mega Blockbuster Stroke and everything else you get for free with CUV and many small loss making Biotechs with high valuations just on the hope that their Phase 1 or 2 will one day become a blockbuster like Stroke.

Not using the buyback at all is quite ridiculous, they had good momentum with the announcement and follow up statement that the buyback would be expanded if shorters didn't 'get the message' and then great news potential competitor Disc flunked their EPP trial. All this led to great buying and shorts had to pump in enormous amounts of fake Sell liquidity to control the price according to ASIC data. Since then they have continued to drop the price like last Friday, a 6% drop which was 3% below VWAP shows massive manipulation designed to scare investors, shorts have a clear history with doing this at CUV and the company just let it happen last week when they have the tools to stop this now (over time). Still manipulating the closing price to 3% below VWAP might even be enough to attract ASIC attention if they have any heartbeat at all but that is a long shot - still the shorting game is stacked in favour of shorters they can take 6% off with fake liquidity and circular trades in one day but CUV can only buyback up to a limit of 5% above previous 5 days average VWAP. That is why the buyback will work over time but it needs to get moving with some aggression and then maintain that momentum (and maybe management buying would also send a signal). Either way it's a great entry point for new investors and should make new US recruit Mr Clouston's job quite easy in the States. It shouldn't take too many large investors to get this thing moving, unless shorters want to make cash printing CUV the most shorted company in Australia against all logic.

All IMO DYOR

Expand

Is there buy volume restriction(based on average volume sold ) or only VWAP 5% restriction for Buy back?

CUV Price at posting: $14.38 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

First 5 Last

Add CUV (ASX) to my watchlist

(20min delay)
Last $13.28		Change -0.250(1.85%)		Mkt cap ! $664.8M

Open	High	Low	Value	Volume
$13.55	$13.62	$13.25	$1.157M	86.45K

Buyers (Bids)

No.	Vol.	Price($)
1	227	$13.28

Sellers (Offers)

Price($)	Vol.	No.
$13.42	228	1

View Market Depth

No.	Vol.	Price($)
4	3077	13.250
1	10	13.240
1	500	13.230
1	200	13.220
7	2791	13.200

Price($)	Vol.	No.
13.500	800	1
13.530	700	1
13.550	2500	1
13.890	729	1
14.000	2020	2

Last trade - 16.10pm 15/11/2024 (20 minute delay)

CUV (ASX) Chart

Is there buy volume restriction(based on average volume sold )...

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Banshee's historic trenches prove rich in antimony and gold for GDM

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Is there buy volume restriction(based on average volume sold )...

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Banshee's historic trenches prove rich in antimony and gold for GDM

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News